Fatemah O F O Alshammari
Overview
Explore the profile of Fatemah O F O Alshammari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention
Al-Saraireh Y, Alshammari F, Abu-Azzam O, Al-Dalain S, Al-Sarayra Y, Haddad M, et al.
Biomedicines
. 2023 Nov;
11(11).
PMID: 38001897
Over the past decade, there have been significant developments in treatment for ovarian cancer, yet the lack of targeted therapy with few side effects still represents a major issue. The...
2.
Al-Saraireh Y, Alshammari F, Satari A, Al-Mahdy Y, Almuhaisen G, Abu-Azzam O, et al.
Medicina (Kaunas)
. 2022 Sep;
58(9).
PMID: 36143940
Background and Objective: Ovarian cancer is a leading cause of death in females. Since its treatment is challenging and causes severe side effects, novel therapies are urgently needed. One of...
3.
Al-Saraireh Y, Alshammari F, Youssef A, Al-Sarayreh S, Almuhaisen G, Alnawaiseh N, et al.
Onco Targets Ther
. 2021 Nov;
14:5249-5260.
PMID: 34803385
Purpose: Colon cancer is a leading cause of mortality worldwide. It has a relatively poor prognosis; therefore, new therapies are needed. One of the tumour-related enzymes that has gained considerable...
4.
Al-Saraireh Y, Alshammari F, Youssef A, Al-Tarawneh F, Al-Sarayreh S, Almuhaisen G, et al.
Breast Cancer (Dove Med Press)
. 2021 Oct;
13:565-574.
PMID: 34675653
Purpose: Triple-negative breast cancer (TNBC) is characterized by high mortality rate, and its clinical management is difficult and complex. Therefore, there is a need for extensive efforts aimed at accelerating...
5.
Alshammari F, Al-Saraireh Y, Youssef A, Al-Sarayra Y, Alrawashdeh H
Interact J Med Res
. 2021 Oct;
10(4):e31150.
PMID: 34636736
Background: Current standard treatments for patients with recurrent cervical cancer are not very effective and are associated with severe toxicity. Recently, the rational approach for the discovery of new therapies...
6.
Al-Saraireh Y, Alshammari F, Youssef A, Al-Sarayra Y, Al-Saraireh R, Al-Muhaisen G, et al.
Curr Oncol
. 2021 Sep;
28(5):3573-3584.
PMID: 34590601
Background: cervical cancer is one of the most common malignancies in women worldwide and its management remains challenging and complex. As Cytochrome4Z1 (CYP4Z1) is overexpressed in many tumours, its expression...
7.
Alshammari F, Al-Saraireh Y, Youssef A, Al-Sarayra Y, Alrawashdeh H
Onco Targets Ther
. 2021 Aug;
14:4309-4318.
PMID: 34366675
Purpose: Treatment of metastatic breast cancer patients is challenging and remains a major underlying cause of female mortality. Understanding molecular alterations in tumor development is critical to identify novel biomarkers...
8.
Al-Saraireh Y, Alshammari F, Youssef A, Al-Sarayreh S, Almuhaisen G, Alnawaiseh N, et al.
Sci Rep
. 2021 Mar;
11(1):5581.
PMID: 33692504
Bladder cancer is the tenth most common cancer worldwide, where its burden remains a challenge and needs new novel therapies. Several reports indicate expression of CYP4Z1 and CYP1B1 in many...